Sarecycline

CHEMBL2364632 Phase 4 승인됨 Small molecule
Half-Life
Bioavailability
Protein Binding
Molecular Weight
487.5 g/mol
LogP
1.1
Phase
4

Sarecycline is a narrow-spectrum tetracycline-class antibiotic with anti-inflammatory properties, approved for the treatment of inflammatory lesions of non-nodular moderate-to-severe acne vulgaris. Unlike broad-spectrum tetracyclines, its narrow spectrum reduces disruption of gut microbiota while inhibiting bacterial protein synthesis via binding to the 30S ribosomal subunit. Investigational use in stroke has been proposed based on its matrix metalloproteinase inhibitory and anti-neuroinflammatory properties.

분자량

487.5000 g/mol

LogP

1.10

TPSA

174.00 Ų

리핀스키 5의 법칙

통과

치료 영역

Pharmacokinetics (PK)

Pharmacodynamics (PD)

2D 구조

SVG PNG

Cite this structure


                        

Embed this structure


                        

SMILES

CON(C)Cc1ccc(O)c2c1C[C@H]1C[C@H]3[C@H](N(C)C)C(O)=C(C(N)=O)C(=O)[C@@]3(O)C(O)=C1C2=O

InChI

InChI=1S/C24H29N3O8/c1-26(2)18-13-8-11-7-12-10(9-27(3)35-4)5-6-14(28)16(12)19(29)15(11)21(31)24(13,34)22(32)17(20(18)30)23(25)33/h5-6,11,13,18,28,30-31,34H,7-9H2,1-4H3,(H2,25,33)/t11-,13-,18-,24-/m0/s1

Molecular Formula

C24H29N3O8

HBD / HBA

5 / 10

회전 가능 결합

5

무거운 원자

35

No targets recorded

Target interaction data is not yet available for this drug.

No interactions recorded

Drug interaction data is not yet available for this compound.

No side effects recorded

Side effect data is not yet available for this drug.

자주 묻는 질문

Sarecycline is a narrow-spectrum tetracycline-class antibiotic with anti-inflammatory properties, approved for the treatment of inflammatory lesions of non-nodular moderate-to-severe acne vulgaris. Unlike broad-spectrum tetracyclines, its narrow spectrum reduces disruption of gut microbiota while inhibiting bacterial protein synthesis via binding to the 30S ribosomal subunit. Investigational use in stroke has been proposed based on its matrix metalloproteinase inhibitory and anti-neuroinflammatory properties.

Yes, Sarecycline is an approved drug. It has reached clinical phase 4. It is classified as a Small molecule.

{# References & Data Sources section for drug detail pages. Renders standard pharmacological database links plus the drug's data_sources field. #}

References & Data Sources

  • ChEMBL — European Bioinformatics Institute (EBI). CHEMBL2364632. Open-access bioactivity database.
  • PubChem — National Center for Biotechnology Information (NCBI). CID 54681908. Chemical information database.

Data aggregated from publicly available pharmacological databases. Last updated 2026-03-28.

의학적 면책조항

This content is for educational and informational purposes only. It is not a substitute for professional medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider before making medication decisions.

Data sources: ChEMBL, PubChem, DailyMed.